Previous close | 0.1000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 7.50 |
Expiry date | 2024-07-19 |
Day's range | 0.1000 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | 35 |
MINNEAPOLIS, June 26, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to result in gross proceeds of $11.8 million. A placement agent was not used in connection with this private placement.
MINNEAPOLIS, June 26, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it plans to expand its DM199 (rinvecalinase alfa; recombinant human tissue kallikrein-1 (rhKLK1)) clinical development program into preeclampsia. Preeclampsia is a life-threatening pregnancy-associated vascular disorder characterized by new onset hypertension with proteinuria, and/or end organ
We can readily understand why investors are attracted to unprofitable companies. For example, although...